Telik Reports Positive Data Demonstrating Synergy in Combination
and Highly Statistically Significant Effect of Telcyta as
Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
PALO ALTO, Calif., April 17, 2007 /PRNewswire-FirstCall/ --
Telik, Inc. announced the presentation today of results from aPhase 2 clinical trial of the triplet combination of TELCYTA(R)(canfosfamide HCl, TLK286), carboplatin and paclitaxel in thefirst-line treatment of advanced non-small cell lung cancer. Theresults include highly statistically and clinically significantimprovement in bot...
Telik Announces Telcyta Clinical and Preclinical Presentations at
AACR Meeting
PALO ALTO, Calif., April 09, 2007 /PRNewswire-FirstCall/ --
Telik, Inc. announced that updated clinical data from itsmulticenter Phase 2 trial of the triplet combination of TELCYTA(R)(canfosfamide HCl, TLK286), carboplatin and paclitaxel will bepresented at the 98th annual meeting of the American Associationfor Cancer Research (AACR) in Los Angeles. Preclinical studies ofcellular and mole...